BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by t...
CERo Therapeutics Holdings, Inc,an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that d...
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infectio...
Enter Generative AI: A Paradigm Shift Today, generative AI is changing this equation. Unlike traditional AI that analyzes existing data, generative AI can...
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...
Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a U...
Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private...
Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negoti...
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support developm...
SpringWorks Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Europe...
Eli Lilly and Company announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (d...
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline ...
JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered ...
Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small...
© 2025 Biopharma Boardroom. All Rights Reserved.
